

Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Primary IR Contact

Melissa Lueke
Executive Vice President
Chief Financial Officer
Meridian Bioscience, Inc.

Stock Performance

VIVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$14.85
Change (%)	▲ 0.03 (0.13%)
Volume	32,169
52 Week Low	\$10.75
Market Cap	\$630,935,104
Rolling EPS	0.51
PE Ratio	29.277
Shares Outstanding	42,203,017

Data as of 11/17/17 11:38 a.m. ET



Recent Press Releases

- 11/9/2017
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance
- 10/23/2017
Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
- 10/19/2017
Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance
- 10/16/2017
Meridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017
- 10/10/2017
Meridian Bioscience, Inc. Appoints Jack Kenny as Chief Executive Officer


Upcoming Events

There are currently no events scheduled.

Recent SEC Filings

Filing Date	Form	Description
11/13/17	4	Statement of changes in beneficial ownership of securities
11/13/17	4	Statement of changes in beneficial ownership of securities
11/13/17	4	Statement of changes in beneficial ownership of securities
11/13/17	4	Statement of changes in beneficial ownership of securities

Analyst Estimates / Ratings



Management

John A. Kraeutler

Chairman of the Board, Chief Executive Officer

Lawrence J. Baldini

Executive Vice President and President, Global Operations

Marco Calzavara

President, Meridian Bioscience Europe

Richard L. Eberly

Executive Vice President, President and Chief Commercial Officer

Slava A. Elagin

Executive Vice President, Research and Product Development

Melissa A. Lueke

Executive Vice President, Chief Financial Officer

Susan D. Rolih

Executive Vice President Regulatory Affairs and Quality Assurance

Lourdes G. Weltzien

Vice President & General Manager, President Asia Pacific Markets

Amy M. Winslow

Executive Vice President, President and CEO Magellan Diagnostics

EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Dec 17	0.15	0.16	0.16
QTR	Mar 18	0.20	0.21	0.21
QTR	Jun 18	0.17	0.17	0.17
QTR	Sep 18	0.15	0.15	0.15
FY	Sep 18	0.66	0.68	0.68
FY	Sep 19	0.72	0.73	0.72

Board of Directors

John A. Kraeutler

Chairman of the Board, Chief Executive Officer

James M. Anderson

Retired President and Chief Executive Officer Cincinnati Children's Hospital Medical Center

David C. Phillips

Co-founder Cincinnati Works, Inc

Dwight (Dee) E. Ellingwood

President, D.E.E. Strategy Consulting, LLC

John C. McIlwraith

Co-founder Allos Ventures

Catherine A. Sazdanoff

Chief Business Officer of Strata Oncology, Inc

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	249	562.67	92.5	39,027,592
Mutual Fund	289	301.56	48.9	20,641,658
Insider *	14	14.94	2.4	993,990

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Brown Capital Management, LLC	5,493,466	13.0	-156,991	09/30/17
BlackRock Institutional Trust Company, N.A.	4,857,304	11.5	71,330	09/30/17
The Vanguard Group, Inc.	4,042,270	9.6	23,285	09/30/17
Renaissance Technologies LLC	2,051,776	4.9	84,476	09/30/17
Dimensional Fund Advisors, L.P.	1,748,848	4.1	80,877	09/30/17
State Street Global Advisors (US)	1,204,324	2.9	-26,768	09/30/17
Norges Bank Investment Management (NBIM)	1,136,022	2.7	0	12/31/16
New York State Common Retirement Fund	1,059,987	2.5	0	09/30/17
M & G Investment Management Ltd.	923,400	2.2	0	09/30/17
Millennium Management LLC	731,335	1.7	395,802	09/30/17

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed